El resfriado y la gripe: prevenci ón, síntomas y tratamientos

En gran parte del hemisferio norte, ésta es la temporada perfecta para contraer un resfriado, la influenza (gripe) y otras enfermedades respiratorias. Aunque los virus contagiosos se mantienen activos durante todo el año, la mayoría de las infecciones ocurre en el otoño y el invierno.
Source: FDA Consumer Health Information Updates - Category: Consumer Health News Authors: Source Type: news

Related Links:

Publication date: Available online 18 October 2019Source: Veterinary MicrobiologyAuthor(s): Xuejiao Han, Luca D. Bertzbach, Michael VeitAbstractIn contrast to human influenza viruses that replicate in the respiratory tract and are airborne transmitted, avian viruses also replicate in gut epithelial cells and are transmitted via the fecal-oral route. On this route, the virus is exposed to destructive fluids of the digestive tract, which are acidic and contain the proteases pepsin (gizzard) or chymotrypsin and trypsin (intestine). Only the latter enzyme activates virus by cleaving hemagglutinin (HA) into HA1 and HA2 subunits...
Source: Veterinary Microbiology - Category: Veterinary Research Source Type: research
Background: Influenza virus is one of the most common respiratory pathogens for all age groups and may cause seasonal outbreaks. Our aim was to identify risk groups and factors associated with severe clinical course including mortality in children with influenza-related lower respiratory tract infection (LRTI). Methods: We conducted a retrospective study in children hospitalized with influenza virus LRTI from 2008 to 2018. Data on demographic features, influenza type, viral coinfection, primary and secondary bacterial infections (SBIs), time of onset of antiviral treatment, comorbidities, hospitalization length, pedia...
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Original Studies Source Type: research
Publication date: Available online 11 September 2019Source: Journal of Hospital InfectionAuthor(s): E. Skelly, M. Skally, M. Foley, L. Gaughan, F. Duffy, K. Burns, H. Humphreys, F. Fitzpatrick
Source: Journal of Hospital Infection - Category: Infectious Diseases Source Type: research
ConclusionsSOPs may provide a good starting point for increasing adult immunization coverage rates. Using additional interventions, quality-based metrics, or incentives could lead to sustained adult immunization prioritization.
Source: American Journal of Infection Control - Category: Infectious Diseases Source Type: research
Conditions:   Influenza;   Critical Illness Intervention:   Diagnostic Test: influenza screening Sponsor:   University of Bordeaux Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: A variety of approaches can be effective. Focusing training sessions for medical practice teams on certain diseases may be of greater benefit than vacci- nation-centered training sessions. Reminder systems for doctors should be more reliably implemented. Simple strategies are perhaps the most suitable ones in the heterogeneous population of chronically ill persons. The limitations of this system- atic review include the heterogeneity of the studies that we examined and the small number of studies in each category. PMID: 31617479 [PubMed - in process]
Source: Deutsches Arzteblatt International - Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research
This study was conducted to enhance the rate of advance care planning conversations and documentation by improving knowledge, attitudes, and skills of caregivers.      Read more   Violence and Trauma ...
Source: Johns Hopkins University and Health Systems Archive - Category: Nursing Source Type: news
Roche today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-related complications.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
South San Francisco, CA -- October 17, 2019 -- Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza™ (baloxavir marboxil)...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
A recent study in this journal compared codon usage among NA subtypes (N1, N2, N6, and N8)  of H5Nx highly pathogenic avian influenza A viruses (HPAIVs) and suggested that codon usage in N1 subtype is better adapted to its host than the epidemic NA subtypes (N6 and N8), which had fewer number of human cases compared to the N1 subtype.1 To date, there are 18 known HA subtypes (H1-H18) and 11 known NA subtypes (N1-N11)2. However, only N1 and N2 subtypes have been reported to cause pandemics (H1N1 for the 1918 and 2009 pandemics; H2N2 for the 1957 pandemic; and H3N2 for the 1968 pandemic) or seasonal outbreaks in humans3.
Source: Journal of Infection - Category: Infectious Diseases Authors: Tags: Letter to the Editor Source Type: research
More News: Health | Influenza